Pfizer Drug Combination to Treat Colorectal Cancer Cleared by FDA

MT Newswires Live
2024-12-21

Pfizer (PFE) Friday said the US Food and Drug Administration approved a combination of its Braftovi cancer drug with Eli Lilly's (LLY) Erbitux medication and three other chemotherapies to treat patients with metastatic colorectal cancer with a BRAF V600E mutation as detected through an FDA-approved test.

The regulatory approval followed phase 3 study. Initial data showed patients in the active arm of the trial had an objective response rate of 61%, compared with a 40% rate in chemotherapy, with or without bevacizumab, Pfizer said.

Median duration of response for the Braftovi patients was 13.9 months, compared with 11.1 months in the other arm, the company said, adding testing is ongoing, with complete trial data to be presented at future medical meetings.

Pfizer shares recently were more than 2% higher.

Price: 26.38, Change: +0.61, Percent Change: +2.37

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10